---
layout: default
title: Nystatin
description: "Nystatin 的老藥新用潛力分析。初步證據等級 L4，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 中證據等級 (L3-L4)
nav_order: 116
evidence_level: L3
indication_count: 10
---

# Nystatin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L4</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nystatin：從抗真菌藥物到外陰陰道炎

## 一句話總結

<p class="key-answer" data-question="Nystatin 可以用於治療什麼新適應症？">
Nystatin 是一種抗真菌藥物，通常用於治療由念珠菌引起的感染。
TxGNN 模型預測它可能對**外陰陰道炎 (Vulvovaginitis)** 有效，
目前有 **0 個臨床試驗**和 **20 篇文獻**支持這個方向。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 對革蘭氏陽性菌及陰性菌所引起之感染症 |
| 預測新適應症 | vulvovaginal candidiasis、vulvovaginitis、disease of orbital region、disease of orbital part of eye adnexa、cystic teratoma、spinal cord dermoid cyst、postmenopausal atrophic vaginitis、biotin metabolic disease、oral candidiasis、candidiasis |
| TxGNN 預測分數 | 99.92% |
| 證據等級 | L4 |
| 台灣上市 | ✓ 已上市 |
| 許可證數 | 20 張 |
| 建議決策 | Proceed with Guardrails |






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. vulvovaginitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.92%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p><p class="key-answer" data-question="這個藥物的作用機轉是什麼？"></p>
<p>目前缺乏詳細的作用機轉資料。根據已知資訊，Nystatin 是抗真菌藥物的一部分，</p>
<p>其成分在由念珠菌引起的感染症中的療效已被證實，機轉上可能適用於外陰陰道炎。</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>此預測基於藥物的作用機轉，與現有臨床證據方向一致。</p>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25775428/" target="_blank">25775428</a></td><td>2015</td><td>Article</td><td>BMJ clinical evidence</td><td>Candidiasis (vulvovaginal).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21774671/" target="_blank">21774671</a></td><td>2011</td><td>Article</td><td>Journal of women&#x27;s health (200</td><td>Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4919155/" target="_blank">4919155</a></td><td>1970</td><td>Article</td><td>The Medical clinics of North A</td><td>Nystatin.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12228137/" target="_blank">12228137</a></td><td>2002</td><td>Article</td><td>BMJ (Clinical research ed.)</td><td>Vulvovaginal candidiasis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39771534/" target="_blank">39771534</a></td><td>2024</td><td>Article</td><td>Pharmaceutics</td><td>Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11363911/" target="_blank">11363911</a></td><td>1996</td><td>Article</td><td>Journal of the International A</td><td>Candidiasis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21718579/" target="_blank">21718579</a></td><td>2010</td><td>Article</td><td>BMJ clinical evidence</td><td>Candidiasis (vulvovaginal).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3873872/" target="_blank">3873872</a></td><td>1985</td><td>Article</td><td>American journal of obstetrics</td><td>Vaginitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4601917/" target="_blank">4601917</a></td><td>1974</td><td>Article</td><td>The Medical clinics of North A</td><td>Vaginitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8193418/" target="_blank">8193418</a></td><td>1994</td><td>Article</td><td>The Annals of pharmacotherapy</td><td>Metronidazole hypersensitivity.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10470518/" target="_blank">10470518</a></td><td>1999</td><td>Article</td><td>Comprehensive therapy</td><td>Vulvovaginitis in healthy women.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20406393/" target="_blank">20406393</a></td><td>2011</td><td>Article</td><td>Mycoses</td><td>In vitro fluconazole and nystatin susceptibility and clinical outcome in complic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32104010/" target="_blank">32104010</a></td><td>2020</td><td>Article</td><td>Infection and drug resistance</td><td>Antifungal Activity of ZnO Nanoparticles and Nystatin and Downregulation of SAP1...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16047929/" target="_blank">16047929</a></td><td>2005</td><td>Article</td><td>Ceska gynekologie</td><td>[&quot;Mixed&quot; and &quot;miscellaneous&quot; vulvovaginitis: diagnostics and therapy of vaginal ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16620487/" target="_blank">16620487</a></td><td>2005</td><td>Article</td><td>Clinical evidence</td><td>Candidiasis (vulvovaginal).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31969236/" target="_blank">31969236</a></td><td>2019</td><td>Article</td><td>Acta dermatovenerologica Croat</td><td>Effectiveness and Pharmacokinetic evaluation of Geonistin® (Oxytetracyline and N...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37023426/" target="_blank">37023426</a></td><td>2023</td><td>Article</td><td>Journal of infection in develo</td><td>Comparison of tea tree oil 5%, tea tree oil 10%, and nystatin inhibition zones a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4584828/" target="_blank">4584828</a></td><td>1973</td><td>Article</td><td>The Journal of obstetrics and </td><td>A trial of clotrimazole and nystatin in vaginal moniliasis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19454049/" target="_blank">19454049</a></td><td>2007</td><td>Article</td><td>BMJ clinical evidence</td><td>Candidiasis (vulvovaginal).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30359236/" target="_blank">30359236</a></td><td>2018</td><td>Article</td><td>BMC microbiology</td><td>Nystatin enhances the immune response against Candida albicans and protects the ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. disease of orbital region</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（2 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03178149" target="_blank">NCT03178149</a></td><td>PHASE1</td><td>RECRUITING</td><td>42</td><td>A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06637423" target="_blank">NCT06637423</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>32</td><td>A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Int...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. disease of orbital part of eye adnexa</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. cystic teratoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. spinal cord dermoid cyst</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. postmenopausal atrophic vaginitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. biotin metabolic disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.87%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. vulvitis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25775428/" target="_blank">25775428</a></td><td>2015</td><td>Article</td><td>BMJ clinical evidence</td><td>Candidiasis (vulvovaginal).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21774671/" target="_blank">21774671</a></td><td>2011</td><td>Article</td><td>Journal of women&#x27;s health (200</td><td>Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4919155/" target="_blank">4919155</a></td><td>1970</td><td>Article</td><td>The Medical clinics of North A</td><td>Nystatin.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12228137/" target="_blank">12228137</a></td><td>2002</td><td>Article</td><td>BMJ (Clinical research ed.)</td><td>Vulvovaginal candidiasis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21718579/" target="_blank">21718579</a></td><td>2010</td><td>Article</td><td>BMJ clinical evidence</td><td>Candidiasis (vulvovaginal).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3873872/" target="_blank">3873872</a></td><td>1985</td><td>Article</td><td>American journal of obstetrics</td><td>Vaginitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4601917/" target="_blank">4601917</a></td><td>1974</td><td>Article</td><td>The Medical clinics of North A</td><td>Vaginitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8193418/" target="_blank">8193418</a></td><td>1994</td><td>Article</td><td>The Annals of pharmacotherapy</td><td>Metronidazole hypersensitivity.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20406393/" target="_blank">20406393</a></td><td>2011</td><td>Article</td><td>Mycoses</td><td>In vitro fluconazole and nystatin susceptibility and clinical outcome in complic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16620487/" target="_blank">16620487</a></td><td>2005</td><td>Article</td><td>Clinical evidence</td><td>Candidiasis (vulvovaginal).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31969236/" target="_blank">31969236</a></td><td>2019</td><td>Article</td><td>Acta dermatovenerologica Croat</td><td>Effectiveness and Pharmacokinetic evaluation of Geonistin® (Oxytetracyline and N...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37023426/" target="_blank">37023426</a></td><td>2023</td><td>Article</td><td>Journal of infection in develo</td><td>Comparison of tea tree oil 5%, tea tree oil 10%, and nystatin inhibition zones a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4584828/" target="_blank">4584828</a></td><td>1973</td><td>Article</td><td>The Journal of obstetrics and </td><td>A trial of clotrimazole and nystatin in vaginal moniliasis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19454049/" target="_blank">19454049</a></td><td>2007</td><td>Article</td><td>BMJ clinical evidence</td><td>Candidiasis (vulvovaginal).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30359236/" target="_blank">30359236</a></td><td>2018</td><td>Article</td><td>BMC microbiology</td><td>Nystatin enhances the immune response against Candida albicans and protects the ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10470518/" target="_blank">10470518</a></td><td>1999</td><td>Article</td><td>Comprehensive therapy</td><td>Vulvovaginitis in healthy women.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11188008/" target="_blank">11188008</a></td><td>2000</td><td>Article</td><td>Akusherstvo i ginekologiia</td><td>[Polygynax].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21918792/" target="_blank">21918792</a></td><td>2012</td><td>Article</td><td>Acta dermato-venereologica</td><td>Efficacy of fluconazole and nystatin in the treatment of vaginal Candida species...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3510698/" target="_blank">3510698</a></td><td>1986</td><td>Article</td><td>CMAJ : Canadian Medical Associ</td><td>Vaginitis: current microbiologic and clinical concepts.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37029724/" target="_blank">37029724</a></td><td>2023</td><td>Article</td><td>Journal of obstetrics and gyna</td><td>Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. commissural lip fistula</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. osteoradionecrosis of the mandible</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 內衛藥製字第003610號 | 立達泰定膠囊 | 膠囊劑 | 對革蘭氏陽性菌及陰性菌所引起之感染症 |
| 衛部藥輸字第027982號 | 耐絲菌素 | 粉劑 | 抗生素 |
| 衛署藥製字第006513號 | 都愛淨口服錠 | 膜衣錠 | 由念珠菌所引起之局部感染及腸念珠菌病 |
| 衛署藥製字第018023號 | "優良"優膚力霜劑 | 乳膏劑 | 過敏性、發炎性與念珠菌黴菌及酵母菌之皮膚感染 |
| 衛署藥製字第034747號 | 紐黴素軟膏１００，０００單位/公克（耐絲菌素） | 軟膏劑 | 用於治療白色念珠球菌所引起之皮下及黏膜皮膚之黴菌感染症。 |

## 安全性考量

- **藥物交互作用**：Nystatin 與 Cyclosporine、Octreotide、Cyanocobalamin、Calcitriol 和 Folic acid 等藥物可能有未知的交互作用。

## 結論與下一步

**決策：Proceed with Guardrails**

**理由：**
雖然缺乏直接的臨床試驗支持，但有多篇文獻指出 Nystatin 在外陰陰道念珠菌病中的潛在應用。

**若要推進需要：**
- 詳細的藥物作用機轉資料（MOA）
- 進一步的臨床試驗以驗證其療效和安全性
- 針對特定族群的安全性監測計畫


---

## 相關藥物報告

- [Silicon Dioxide]({{ "/drugs/silicon_dioxide/" | relative_url }}) - 證據等級 L4
- [Pralatrexate]({{ "/drugs/pralatrexate/" | relative_url }}) - 證據等級 L4
- [Hydroquinone]({{ "/drugs/hydroquinone/" | relative_url }}) - 證據等級 L4
- [Minoxidil]({{ "/drugs/minoxidil/" | relative_url }}) - 證據等級 L4
- [Ropinirole]({{ "/drugs/ropinirole/" | relative_url }}) - 證據等級 L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Nystatin老藥新用驗證報告. https://twtxgnn.yao.care/drugs/nystatin/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_nystatin,
  title = {Nystatin老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/nystatin/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
